650608-21-2

Upstream product

• 64-18-6 formic acid 
• 6298-96-0 1(R)-(4-methoxyphenyl)-ethylamine 
• 83834-91-7 N-formyl 1-(4-methoxyphenyl)ethylamine 
• 6298-96-0 1-(4-methoxyphenyl)ethanamine 

Relevant academic research and scientific papers

Structure based drug design and in vitro metabolism study: Discovery of N-(4-methylthiophenyl)-N,2-dimethyl-cyclopenta[d]pyrimidine as a potent microtubule targeting agent

We report a series of tubulin targeting agents, some of which demonstrate potent antiproliferative activities. These analogs were designed to optimize the antiproliferative activity of 1 by varying the heteroatom substituent at the 4′-position, the basicity of the 4-position amino moiety, and conformational restriction. The potential metabolites of the active compounds were also synthesized. Some compounds demonstrated single digit nanomolar IC50 values for antiproliferative effects in MDA-MB-435 melanoma cells. Particularly, the S-methyl analog 3 was more potent than 1 in MDA-MB-435 cells (IC50 = 4.6 nM). Incubation of 3 with human liver microsomes showed that the primary metabolite of the S-methyl moiety of 3 was the methyl sulfinyl group, as in analog 5. This metabolite was equipotent with the lead compound 1 in MDA-MB-435 cells (IC50 = 7.9 nM). Molecular modeling and electrostatic surface area were determined to explain the activities of the analogs. Most of the potent compounds overcome multiple mechanisms of drug resistance and compound 3 emerged as the lead compound for further SAR and preclinical development.

Chiral initiator-induces self-disproportionation of enantiomers via achiral chromatography: Application to enantiomer separation of racemate

We report here the theoretical design and proof of principle of the first example of a conceptually new approach for the preparation of enantiomerically pure compounds from the racemates by chiral initiator-induced Self-Disproportionation of Enantiomers (SDE) via achiral chromatography.